Paper41809263
Extracellular vesicles in cancer immunotherapy: Therapeutic, challenges and clinical progress.
Manoochehri H and 10 others. Asian J Pharm Sci, 2025. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Extracellular vesicles in cancer immunotherapy: Therapeutic, challenges and clinical progress. Papers, record 41809263. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41809263
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Extracellular vesicles in cancer immunotherapy: Therapeutic, challenges and clinical progress.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References245
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36582304 | M2-like macrophage-derived exosomes facilitate metastasis in non-small-cell lung cancer by delivering integrin αVβ3. | MedComm (2020) | 2023 | https://conductscience.org/library/papers/36582304 | PubMed |
| 2 | 35163020 | Exosomal MALAT1 Derived from High Glucose-Treated Macrophages Up-Regulates Resistin Expression via miR-150-5p Downregulation. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35163020 | PubMed |
| 3 | 36123730 | A review on exosomes application in clinical trials: perspective, questions, and challenges. | Cell Commun Signal | 2022 | https://conductscience.org/library/papers/36123730 | PubMed |
| 4 | 23170255 | Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. | Oncoimmunology | 2012 | https://conductscience.org/library/papers/23170255 | PubMed |
| 5 | 35056304 | Microfluidic Approaches and Methods Enabling Extracellular Vesicle Isolation for Cancer Diagnostics. | Micromachines (Basel) | 2022 | https://conductscience.org/library/papers/35056304 | PubMed |
| 6 | 33713953 | Isolation of extracellular vesicles with combined enrichment methods. | J Chromatogr B Analyt Technol Biomed Life Sci | 2021 | https://conductscience.org/library/papers/33713953 | PubMed |
| 7 | 23584393 | Extracellular vesicles: biology and emerging therapeutic opportunities. | Nat Rev Drug Discov | 2013 | https://conductscience.org/library/papers/23584393 | PubMed |
| 8 | 31963216 | Extracellular Vesicles for Cancer Therapy: Impact of Host Immune Response. | Cells | 2020 | https://conductscience.org/library/papers/31963216 | PubMed |
| 9 | 32547069 | A Combination of circRNAs as a Diagnostic Tool for Discrimination of Papillary Thyroid Cancer. | Onco Targets Ther | 2020 | https://conductscience.org/library/papers/32547069 | PubMed |
| 10 | 34919343 | A brief history of nearly EV-erything - The rise and rise of extracellular vesicles. | J Extracell Vesicles | 2021 | https://conductscience.org/library/papers/34919343 | PubMed |
| 11 | 33253966 | Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. | Biomaterials | 2021 | https://conductscience.org/library/papers/33253966 | PubMed |
| 12 | 34560422 | M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. | Biomaterials | 2021 | https://conductscience.org/library/papers/34560422 | PubMed |
| 13 | 36922504 | Engineered exosomes from different sources for cancer-targeted therapy. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/36922504 | PubMed |
| 14 | 33107700 | Serum exosomal miR-1269a serves as a diagnostic marker and plays an oncogenic role in non-small cell lung cancer. | Thorac Cancer | 2020 | https://conductscience.org/library/papers/33107700 | PubMed |
| 15 | 30301470 | Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. | BMC Med | 2018 | https://conductscience.org/library/papers/30301470 | PubMed |
| 16 | 27032035 | A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. | JAMA Oncol | 2016 | https://conductscience.org/library/papers/27032035 | PubMed |
| 17 | 33093453 | Exosomal LGALS9 in the cerebrospinal fluid of glioblastoma patients suppressed dendritic cell antigen presentation and cytotoxic T-cell immunity. | Cell Death Dis | 2020 | https://conductscience.org/library/papers/33093453 | PubMed |
| 18 | 29689228 | Exosomes and Ectosomes in Intercellular Communication. | Curr Biol | 2018 | https://conductscience.org/library/papers/29689228 | PubMed |
| 19 | 30723593 | Exosomes from GM-CSF expressing embryonic stem cells are an effective prophylactic vaccine for cancer prevention. | Oncoimmunology | 2019 | https://conductscience.org/library/papers/30723593 | PubMed |
| 20 | 36849892 | Extracellular vesicles derived from mesenchymal stem cells - a novel therapeutic tool in infectious diseases. | Inflamm Regen | 2023 | https://conductscience.org/library/papers/36849892 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42711596 | Extracellular vesicles for next-gen therapeutics and drug delivery. | Mol Biomed | 2026 | https://conductscience.org/library/papers/42711596 | PubMed |
| 42514925 | Proteomic Stability and Ex Vivo Compatibility of a Processed Phospholipoproteic Secretome-Derived Formulation. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42514925 | PubMed |
| 42253953 | Glioma-derived extracellular vesicles as drivers of immunotherapeutic resistance: mechanisms of immune reprogramming and metabolic intervention. | Front Immunol | 2026 | https://conductscience.org/library/papers/42253953 | PubMed |
| 42180894 | Exosomal P4HA3: a promising biomarker for diagnosis and prognosis in gastric cancer. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42180894 | PubMed |
| 41948316 | Editorial: Immune-genetic dynamics in disease progression and therapeutic strategies. | Front Immunol | 2026 | https://conductscience.org/library/papers/41948316 | PubMed |
| 41299768 | Therapeutic potential and mechanistic insights into adipose-derived stem cells and mesenchymal stem cell-derived exosomes in patients with Crohn's disease-associated fistulas: challenges and future perspectives. | Stem Cell Res Ther | 2025 | https://conductscience.org/library/papers/41299768 | PubMed |
| 41281748 | Extracellular matrix dysregulation in aging, calcification, and cancer diseases: insights into cellular senescence, inflammation, and novel therapeutic strategies. | Int J Biol Sci | 2025 | https://conductscience.org/library/papers/41281748 | PubMed |
Genes61
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41809263
GET https://conductscience.org/api/papers/v1/41809263/references?page=2